Vaccine Responses in Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-04

Study Completion Date

2028-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators are conducting a prospective unblinded study of individuals diagnosed with cancer who will receive one or more of the following: influenza, SARS-CoV2 and shingles.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Serologic Response to the SARS-CoV-2 (COVID-19) MRNA-1273 Vaccine in Select Subsets of Oncology Patients

NCT04854980

Covid19 Cancer

COMPLETED

Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers

NCT00319748

Breast Cancer Ovarian Cancer Endometrial Cancer +1 more

COMPLETED PHASE2

Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer

NCT00028496

Adenocarcinoma of the Colon Adenocarcinoma of the Gallbladder Adenocarcinoma of the Pancreas +39 more

COMPLETED PHASE1

Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

NCT00436254

HER2-positive Breast Cancer Stage III Ovarian Epithelial Cancer Stage III Ovarian Germ Cell Tumor +6 more

COMPLETED PHASE1

A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma

NCT01970358

Melanoma

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Vaccinations are indicated for all adults, but the immunogenicity of vaccination has not been assessed in all situations. In particular, immune responses following vaccination have not been studied in the setting of cancer and in the context of various anti-tumor treatments. In this study, the investigators will look at the immune response of subjects receiving vaccination.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Viral Vaccines

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with Cancer

Patients with cancer who are clinically indicated to receive influenza, recombinant shingles and/or SARS-CoV2 vaccine

Influenza vaccination

Intervention Type BIOLOGICAL

one annual dose of inactivated influenza vaccine

SARS-CoV-2 vaccine

Intervention Type BIOLOGICAL

dose of SARS CoV2 vaccine

Zoster Vaccine Recombinant

Intervention Type BIOLOGICAL

first and/or second vaccination for shingles (Herpes zoster)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Influenza vaccination

one annual dose of inactivated influenza vaccine

Intervention Type BIOLOGICAL

SARS-CoV-2 vaccine

dose of SARS CoV2 vaccine

Intervention Type BIOLOGICAL

Zoster Vaccine Recombinant

first and/or second vaccination for shingles (Herpes zoster)

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adults over age 18 who are able to provide consent, who have a diagnosis of cancer, and are willing to receive the influenza, recombinant shingles, and/or SARS-CoV-2 vaccines.